Generic and biosimilar products are still out of reach for many patients in LMICs, reveals new report

The article acknowledges that this is the first time that companies like this have been assessed on their access-to-medicine efforts, and that the report identifes key findings and opportunities for the generic industry to expand access.

The Foundation's CEO, Jayasree Iyer, is quoted: “When it comes to expanding access to medicine, the power of the generics industry is often underestimated. It’s more than the transactional relationship of selling drugs at volume and competing on price. Companies must engage with the unmet medical need globally – for example, by working with local manufacturers to improve supply, by taking steps to safeguard quality, by making their essential products available in more countries, and by addressing affordability for the poorest patients.”

Read the Foundation's report on generic and biosimilar medicine manufacturers.